Orchard Therapeutics PLC
Liz Platts has extensive experience in regulatory operations, starting in 2006 as a Senior Manager at Allergan. Liz later held roles at companies like Datafarm Inc, Reckitt Benckiser Pharmaceuticals, and CSL Behring, before becoming an Associate Director at Orchard Therapeutics in 2021. Liz'smost recent position at EUSA Pharma focused on global regulatory publishing.
Liz Platts completed a Bachelor's Degree in Biochemistry and Pharmacology from King's College London in 1984. Later, they pursued a Bachelor's Degree in Mathematics from The Open University, graduating in 2014. Additionally, they attended Royal Free HSM at an unspecified time for an unspecified degree or field of study.
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.